About Azura Ophthalmics
Azura Ophthalmics is a company based in Tel Aviv (Israel) founded in 1997 by Yair Alster.. Azura Ophthalmics has raised $37.2 million across 3 funding rounds from investors including TPG, Orbimed and Medical Research Commercialisation Fund. Azura Ophthalmics offers products and services including Ophthalmic Keratolytics. Azura Ophthalmics operates in a competitive market with competitors including Remegen, Oyster Point Pharmaceuticals, Biophytis, TearSolutions and Retrotope, among others.
- Headquarter Tel Aviv, Israel
- Founders Yair Alster
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Azura Ophthalmics Pty Ltd
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$37.2 M (USD)
in 3 rounds
-
Latest Funding Round
$20 M (USD), Series C
Oct 22, 2020
-
Investors
TPG
& 5 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Azura Ophthalmics
Azura Ophthalmics offers a comprehensive portfolio of products and services, including Ophthalmic Keratolytics. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Treats root causes of ocular surface and lid margin diseases effectively.
Unlock access to complete
Unlock access to complete
Funding Insights of Azura Ophthalmics
Azura Ophthalmics has successfully raised a total of $37.2M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $20 million completed in October 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series C — $20.0M
-
First Round
First Round
(01 Jun 2014)
- Investors Count 6
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2020 | Amount | Series C - Azura Ophthalmics | Valuation | Orbimed , TPG |
|
| Oct, 2017 | Amount | Series B - Azura Ophthalmics | Valuation | Orbimed , Medical Research Commercialisation Fund | |
| Jun, 2014 | Amount | Series A - Azura Ophthalmics | Valuation | Ganot Capital , Elron Electronic Industries |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Azura Ophthalmics
Azura Ophthalmics has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include TPG, Orbimed and Medical Research Commercialisation Fund. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Founded Year | Domain | Location | |
|
Fund of funds focused on pre-seed and seed-stage companies
|
Founded Year | Domain | Location | |
|
Seed & Early stage Life-Sciences focused VC Firm investing primarily in Australia
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Azura Ophthalmics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Azura Ophthalmics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Azura Ophthalmics Comparisons
Competitors of Azura Ophthalmics
Azura Ophthalmics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Remegen, Oyster Point Pharmaceuticals, Biophytis, TearSolutions and Retrotope, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapies for cancer, autoimmune, and eye diseases are developed.
|
|
| domain | founded_year | HQ Location |
Gene therapies for ophthalmological diseases are developed.
|
|
| domain | founded_year | HQ Location |
Drugs for neuromuscular and age-related diseases are developed.
|
|
| domain | founded_year | HQ Location |
Topical therapeutics for the treatment of dry eye disease
|
|
| domain | founded_year | HQ Location |
Therapeutics for neurodegenerative and ophthalmological diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Azura Ophthalmics
Frequently Asked Questions about Azura Ophthalmics
When was Azura Ophthalmics founded?
Azura Ophthalmics was founded in 1997 and raised its 1st funding round 17 years after it was founded.
Where is Azura Ophthalmics located?
Azura Ophthalmics is headquartered in Tel Aviv, Israel.
Who is the current CEO of Azura Ophthalmics?
Marc Gleeson is the current CEO of Azura Ophthalmics.
Is Azura Ophthalmics a funded company?
Azura Ophthalmics is a funded company, having raised a total of $37.2M across 3 funding rounds to date. The company's 1st funding round was a Series A of $1.2M, raised on Jun 01, 2014.
What does Azura Ophthalmics do?
Azura Ophthalmics was founded in 1997 in Tel Aviv, Israel, within the ophthalmics sector. A portfolio of compounds combined with a novel drug delivery platform is advanced to address lid margin diseases, including meibomian gland dysfunction, blepharitis, and contact lens discomfort. The lead product, AZR-MD-001, is currently in phase 2 clinical trials for meibomian gland dysfunction, while AZR-MD-002 and AZR-MD-003 remain in pre-clinical development.
Who are the top competitors of Azura Ophthalmics?
Azura Ophthalmics's top competitors include Remegen, Lineage Cell Therapeutics and Oyster Point Pharmaceuticals.
What products or services does Azura Ophthalmics offer?
Azura Ophthalmics offers Ophthalmic Keratolytics.
Who are Azura Ophthalmics's investors?
Azura Ophthalmics has 6 investors. Key investors include TPG, Orbimed, Medical Research Commercialisation Fund, Ganot Capital, and Brandon Capital.